Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027

About this update from Kiora Pharmaceuticals, Inc.

[{"type":"text","content":"Encinitas, California--(Newsfile Corp. - May 9, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced first quarter 2025 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases.","length":292,"tagName":"p"},{"type":"text","content":"Key first quarter and 2025 year-to-date corporate highlights include:","length":69,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Received approval to initiate KLARITY, a Phase 2 clinical trial evaluating KIO-104 for the treatment of retinal inflammation.","length":125,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":125,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Reported preclinical data on KIO-104 at ARVO 2025, further supporting its potential as a treatment for inflammatory and proliferative retinal diseases.","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"Continued patient enrollment in the ongoing functional endpoint study, work designed to validate functional vision outcomes and serve as an on-ramp study to ABACUS-2. This validation effort supports discussions with regulatory bodies that have indicated that this assessment is the likely approvable endpoint for the future registration trial of KIO-301.","length":354,"tagName":"p"}]},{"val":[{"type":"text","content":"Received $1.8 million in reimbursed Q4 2024 R&D expenses from Théa Open Innovation (Laboratoires Théa) for activities related to KIO-301.","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"Ended the quarter with $24.1 million in cash, cash equivalents and short-term investments, along with $2.0 million in collaboration receivables and tax credits.","length":160,"tagName":"p"}]},{"val":[{"type":"text","content":"Extended the projected cash runway into late 2027, a timeframe beyond anticipated data readouts for KLARITY and ABACUS-2, with potential for further extension through achievement of partnership milestones.","length":205,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1011,"olType":false},{"type":"text","content":""In the first quarter, we continued preparations to initiate enrollment in two Phase 2 clinical trials in retinal diseases," said Brian M. Strem, Ph.D., President & Chief Ex...

More updates from Kiora Pharmaceuticals, Inc.